COMPASS Pathways, a mental health treatment business, acquired the designation for its psilocybin therapy for treatment-resistant depression in 2018. In 2019, Usona Institute, a nonprofit health-related researcher, gained the designation to carry on its tests of psilocybin for a treatment for main depressive disorder.We calculated weighted odds rat